Green Cross is focusing its R&D competence on the Biopharmaceutical field, which has relatively higher potential of success and an exclusive market share than synthetics or natural new medicines, based on the experience and technology accumulated for about 30 years since its establishment in 1967.

Main tasks to build a wide range of home/abroad R&D network are as follows:

With its increasingly expanded R&D investment at the highest level of the same industry in the nation, Green Cross is promoting the development of new medicines aiming for the world market as well as the domestic market through the exploration of new materials and early commercialization of the candidate materials.

Particularly, Green Cross is endeavoring the expansion of the network with bioventure corporations. The advanced foreign companies tend to build a wide range of network for a synergy effect that continuously secures the technical competitiveness while enhancing the in-house R&D competence in the segmented biotechnology that has rapidly been changed since mid 1990s.

Starting from ViroMed, a representative bioventure holding a genetic treatment technology, in 1996, there are about 20 bioventure corporations including Macrogen, I.D.gene developing the DNA chip for the genetic test, Genetic jointly developing AIDS vaccine, Nexgen developing the GMO (genetically modified organism) detection kit, Dinona developing the monoclonal antibody and the diagnostic reagent, and Cellontech commercializing the world's second autologous chondrocyte.